AXL and hepatocellular carcinoma: Treatment with MET and AXL inhibitors in Huh-7/SR cells overexpressing Galectin-1 significantly increased the sensitivity of these cells to sorafenib, indicating that Galectin-1 enhances MET/AXL signaling and contributes to sorafenib resistance in HCC cells.